Americafirst Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Americafirst Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$434K	Buy	+7,276	New	+$440K	0.59%	62

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Americafirst Capital Management's EGRX Position: Q3 2017 in Review

Americafirst Capital Management opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017: 7,276 shares worth $434K. The stake represents 0.59% of the portfolio and ranks #62 among its holdings.

169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

Americafirst Capital Management held 7,276 shares of Eagle Pharmaceuticals, Inc. worth $434K as of Q3 2017.
Eagle Pharmaceuticals, Inc. was a new Americafirst Capital Management position in Q3 2017.
Eagle Pharmaceuticals, Inc. made up 0.59% of Americafirst Capital Management's portfolio in Q3 2017, its #62 holding.
169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Americafirst Capital Management's 13F filing for Q3 2017, filed 16 Nov 2017.